A - Educational Analysis * US Equities
Educational Analysis * US Equities

A

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerA
CategoryEducational primer
Last reviewedNovember 10, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Agilent Technologies, Inc. operates under the Healthcare sector, specifically in Medical – Diagnostics & Research. In plain terms, it sells application-focused solutions for life sciences, diagnostics and applied markets: laboratory instruments, software, services and consumables that span the full lab workflow. Following a November 2024 reorganization, Agilent reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. It distributes primarily through a direct sales force, supplemented by distributors, resellers, manufacturers’ representatives and e-commerce.

The margin and return metrics hint at a defensible, asset-light quality franchise. Agilent’s net margin is 19.5% and its ROE sits at 20.5%. A double-digit ROE above 20% shows the business is converting equity capital into profits at a rate that is materially above the cost of capital for a typical industrial or healthcare name, while a nearly 20% net margin suggests pricing power and recurring revenue streams—likely consumables and service contracts—are doing more of the heavy lifting than one-off instrument sales alone.

Financial posture

The stock currently trades at $180.17, carrying a market capitalization of roughly $50.8 billion and a trailing P/E of 35.4. Against net profit margins of 19.5% and ROE of 20.5%, that P/E represents a clear premium: investors are paying up for perceived earnings stability, recurring revenue and long-term life-sciences exposure. The beta is 1.24, meaning the stock has historically moved about 24% more than the broader market, so macro-driven positioning can amplify both rallies and pullbacks. The RSI is 59.2—neither overbought nor oversold—and price sits above the 50-day EMA of $167.19, reflecting near-term strength off that moving average.

Strategic priorities & outlook

Agilent’s most recent 10-K emphasizes that the November 2024 three-segment reorganization is more than cosmetic; it is meant to support a market-focused, customer-centric strategy across Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Operationally, the company is focused on expanding the liquid chromatography application space with new columns, services and ongoing instrument/software enhancements. It is also pushing to improve mass spectrometry performance, sensitivity, precision, robustness, ease of use and onboard intelligence. Finally, Agilent wants to deepen software and service revenue through digitally connected “smart labs” that leverage data analytics, artificial intelligence and robotics.

As of October 31, 2025, Agilent employed about 18,100 people worldwide, with roughly 6,300 in Life Sciences and Diagnostics Markets, 7,400 in Agilent CrossLab and 2,500 in Applied Markets. Its centralized order fulfillment and supply chain organization supports globally dispersed R&D and manufacturing sites across the U.S., Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom. That footprint creates optionality but also complexity, especially if trade or geopolitical conditions shift.

Macro & geopolitical exposure

As a Medical – Diagnostics & Research company, Agilent is exposed to the regulatory and reimbursement backdrop governing diagnostics, laboratory devices and research tools. FDA and equivalent overseas approvals, as well as CMS reimbursement decisions and hospital capital-spending budgets, can all influence instrument replacement cycles and adoption rates. Because it sources and sells globally, currency fluctuations, cross-border tariffs and supply-chain disruptions are relevant risk channels—particularly with manufacturing and R&D spread across China, Malaysia, Europe and North America. More broadly, the industry tends to be sensitive to biopharma funding levels, academic research budgets and commodity/input costs such as specialty chemicals, semiconductors and precision components. None of these factors are unique to Agilent, but the company’s global scale means they can ripple through both revenue and margin lines.

Recent developments

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Agilent has beaten earnings expectations six times, for a beat rate of 86%, with an average earnings surprise of 3%. The average five-day price move in the trading sessions after those reports is +2.44%, classified as an “up” drift.

That headline average, however, conceals real volatility. Looking at the last four reports:

The pattern to remember is this: even on beat quarters, the five-day drift has not reliably followed the direction of the earnings surprise. A strong May 2026 reaction was the outlier; beats in August and November 2025 were followed by short-term givebacks. That makes the upcoming November 23, 2026 report—with a consensus EPS estimate of $1.73—a data point where the immediate price action could easily diverge from whether the company merely clears the number.

Frequently Asked Questions

What does Agilent actually sell?

Agilent provides instruments, software, services and consumables for the entire laboratory workflow, serving life sciences, diagnostics and applied markets. Since a November 2024 reorganization, it has reported through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.

How consistently does Agilent beat earnings?

Over the last eight reported quarters, Agilent beat expectations six times, or 86% of the time, with an average earnings surprise of 3%. However, beating does not guarantee a sustained post-earnings price drift.

What should traders watch around the next earnings report?

The next report is scheduled for November 23, 2026 after the close, with a consensus EPS estimate of $1.73. Traders often focus not just on the beat or miss, but on the magnitude of the surprise and any guidance commentary, because recent history shows the five-day drift can reverse even after a solid quarterly beat.

For a deeper dive into how institutional analysts are interpreting Agilent’s valuation, margin profile and upcoming earnings setup, readers should review the full institutional verdict and consensus mosaic.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 10, 2026
Agilent Technologies, Inc. · Healthcare / Medical - Diagnostics & Research
$50.8BMarket cap
35.4P/E
19.5%Net margin
20.5%ROE
86%Beat rate, last 8Q
3%Avg EPS surprise
2.44%Avg 5-day move after earnings
2026-11-23Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-08-26$1.62$1.49+8.7%+1.68%-2.38%
2026-05-27$1.49$1.41+5.7%+16.87%+18.61%
2026-02-25$1.36$1.37-0.7%-3.01%-3.35%
2025-11-24$1.59$1.58431+0.4%+2.34%-3.12%
2025-08-27$1.37$1.370%--
2025-05-28$1.31$1.26+4%--

Previous A editions

Beyond the primer

Get the institutional verdict on A

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the A verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.